KDR and colorectal carcinoma: Regorafenib, a TKI with multiple targets, such as VEGFR, PDGFR (platelet-derived growth factor receptor), FGFR (fibroblast growth factor receptor), and BRAF, was approved by the FDA to treat metastatic CRC.